

Navana Pharmaceuticals PLC.

**Financial Statements (Un-audited) for
Third Quarter (Q3), FY 2024-25**

Period: 1st July 2024 - 31th March 2025



Navana Pharmaceuticals PLC.
Statement of Financial Position (Un-audited)
As at 31 March 2025


(Amount in BDT)

Particulars	Notes	As at	
		31-Mar-2025	30-Jun-2024
Assets			
Non-Current Assets:			
Property, Plant and Equipment	3.00	5,053,681,137	4,650,941,337
Intangible Asset	3.01	165,000	330,000
Capital Work in Progress	4.00	740,375,561	931,717,844
Right-of-Use Asset	5.00	100,413,822	163,404,672
Investment in Marketable Securities (Fair Value)	6.00	38,723,870	76,920,238
Total Non-Current Assets		5,933,359,390	5,823,314,091
Current Assets:			
Inventories	7.00	1,807,822,786	1,283,188,710
Trade and Other Receivables	8.00	832,694,779	1,020,129,897
Advances, Deposits and Prepayments	9.00	1,779,766,586	2,151,093,999
Goods In Transit	10.00	847,159,625	758,207,036
Cash and Cash Equivalents	11.00	200,072,248	267,770,086
Total Current Assets		5,467,516,024	5,480,389,728
Total Assets		11,400,875,414	11,303,703,819
Equity And Liabilities			
Equity:			
Paid-up Share Capital	12.00	1,074,162,170	1,074,162,170
Share Premium	13.00	448,170,069	448,170,069
Revaluation Reserve	14.00	1,848,295,335	1,848,295,335
Capital Reserve		605,590,148	605,590,148
Unrealized Gain/(Loss) Reserve	6.00	(144,011,059)	(123,143,306)
Retained Earnings		1,035,514,504	708,021,144
Total Equity		4,867,721,167	4,561,095,560
Liabilities			
Non-Current Liabilities:			
Loan from Directors	15.00	30,000,000	30,000,000
Lease Liabilities	16.02	51,872,167	64,500,095
Long Term Loan	17.02	61,909,753	115,319,266
Bond		80,000,000	80,000,000
Deferred Tax Liability	18.00	173,972,956	158,005,471
Total Non-Current Liabilities		397,754,876	447,824,832
Current Liabilities:			
Short Term Loan	19.00	4,603,139,067	5,008,191,502
Lease Liabilities (Current Maturity)	16.01	33,253,637	43,553,958
Long Term Loan (Current Maturity)	17.00	111,547,220	35,366,036
Trade and Other Payables	20.00	1,374,488,214	1,199,906,960
Unclaim Dividend Payable	39.00	12,971,233	7,764,971
Total Current Liabilities		6,135,399,371	6,294,783,427
Total Liabilities		6,533,154,247	6,742,608,259
Total Equity and Liabilities		11,400,875,414	11,303,703,819
Net Asset Value (NAV) Per Share	30.00	45.32	42.46

Annexed notes are integral part of these financial statements.


Finance Director & CFO


Company Secretary


Acting Managing Director


Director


Director


Navana Pharmaceuticals PLC.
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the period from 01 July 2024 to 31 March 2025

(Amount in BDT)

Particulars	Notes	Interim Period		Third Quarter	
		July2024- March'2025	July2023- March'2024	Jan-March'2025	Jan-March'2024
Net Sales	21.00	6,604,436,742	5,032,377,101	2,240,718,731	1,748,739,278
Less: Cost of Good Sold	22.00	3,565,890,580	2,738,507,958	1,228,942,581	984,524,181
Gross Profit		3,038,546,162	2,293,869,143	1,011,776,150	764,215,097
Less: Operating Expenses					
Administrative Expenses	23.00	157,651,134	143,334,588	53,579,737	63,621,604
Selling & Marketing Expenses	24.00	1,369,257,119	1,063,286,050	509,002,531	341,856,605
Distribution Expenses	25.00	414,519,918	349,819,128	125,441,333	111,979,148
Total Operating Expenses		1,941,428,171	1,556,439,766	688,023,601	517,457,357
Operating Profit		1,097,117,991	737,429,377	323,752,549	246,757,740
Less: Finance Expenses	26.00	565,981,270	297,668,525	172,737,198	97,654,000
Add: Other Income/(loss)	27.00	(25,119,893)	1,504,079	(26,574,469)	(11,688,685)
Profit before WPPF & Tax		506,016,828	441,264,931	124,440,882	137,415,055
Contribution to WPPF		24,096,039	21,012,616	5,925,756	6,543,574
Profit before tax		481,920,788	420,252,315	118,515,126	130,871,481
Less: Income Tax		106,976,415	88,646,106	10,448,591	23,583,480
Current Tax	28.00	112,884,898	88,717,806	28,507,507	31,177,263
Deferred Tax Expense/(Income)		(5,908,483)	(71,700)	(18,058,916)	(7,593,784)
Profit after Tax		374,944,373	331,606,209	108,066,535	107,288,001
Other Comprehensive Income					
Unrealized Gain/(loss) on Marketable Security		(20,867,753)	(40,940,887)	(2,334,886)	(23,800,487)
Total Comprehensive Income		354,076,620	290,665,322	105,731,649	83,487,514
Earnings Per Share (EPS)	29.00	3.49	3.09	1.01	1.00

Annexed notes are integral part of these financial statements.


Finance Director & CFO


Company Secretary


Acting Managing Director


Director


Director

Navana Pharmaceuticals PLC.
Statement of Changes in Equity (Un-audited)
For the period from 01 July 2024 to 31 March 2025

As at 31 March 2025

(Amount in BDT)

Particulars	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2024	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(123,143,306)	708,021,144	4,561,095,560
Profit after Tax	-	-	-	-	-	-	374,944,373	374,944,373
14% Cash Dividend for YE 30 June 2024	-	-	-	-	-	-	(47,451,013)	(47,451,013)
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	-	(20,867,753)	-	(20,867,753)
	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(144,011,059)	1,035,514,504	4,867,721,167

Navana Pharmaceuticals PLC.
Statement of Changes in Equity (Un-audited)
For the period from 01 July 2023 to 31 March 2024


As at 31 March 2024

Particulars	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2023	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(46,800,998)	443,028,348	4,372,445,072
Profit after Tax during the period	-	-	-	-	-	-	331,606,209	331,606,209
Received from IPO Share Subscription	-	-	750,000,018	-	-	-	-	750,000,018
Allotment of Shares for IPO	-	-	(750,000,018)	-	-	-	-	(750,000,018)
13% Cash Dividend for YE 30 June 2022	-	-	-	-	-	-	(139,641,082)	(139,641,082)
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	-	(40,940,887)	-	(40,940,887)
	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(87,741,885)	634,993,475	4,523,469,312


Finance Director & CFO


Company Secretary


Acting Managing Director


Director



Director


Navana Pharmaceuticals PLC.
Statement of Cash Flows (Un-audited)
For the period from 01 July 2024 to 31 March 2025

(Amount in BDT)

Particulars	Notes	Interim Period	
		July2024- March'2025	July2023- March'2024
<i>Cash Flows from Operating Activities:</i>			
Cash Received from Customers		6,794,629,272	4,943,185,102
Cash Received from Other Income		19,325,559	6,288,326
Cash Paid to Operational & Others		(5,715,804,773)	(4,778,473,343)
Net cash flows from operating Activities:		1,098,150,059	171,000,086
<i>Cash Flows from Investing Activities:</i>			
Cash Paid for Purchase of Property, Plant & Equipment		(214,285,154)	(440,545,130)
Realized Gain/(loss) from Sale of Marketable Securities		(10,457,145)	971,866
Cash received from Dividend Income		901,146	930,336
Cash Received/(Paid) from Investment in Marketable Securities		38,196,368	14,357,289
Net cash from/(used in) investing activities:		(185,644,785)	(424,285,639)
<i>Cash Flows from Financing Activities:</i>			
Dividend Paid		(42,244,751)	(131,496,940)
Bank & Lease Interest Paid		(534,259,615)	(307,205,954)
Payment against Short Term Borrowings		(405,052,435)	540,831,494
Receipts against Long Term Borrowings		22,771,671	43,442,216
Payment against Lease Liability		(22,928,249)	(4,354,112)
Net cash from/(used in) financing activities		(981,713,379)	141,216,705
Change in Cash and Cash Equivalent		(69,208,105)	(112,068,849)
Cash and Cash Equivalent at the beginning of the period		267,770,086	440,930,216
Effect of Exchange Rate Changes on Cash and Cash Equivalents		1,510,267	60,204
Cash and Cash Equivalent at the end of the period		200,072,248	328,921,571
Net Operating Cash Flow per Share (NOCFPS)	31.00	10.22	1.59


Finance Director & CFO


Company Secretary


Acting Managing Director


Director


Director

Navana Pharmaceuticals PLC.
Notes to the Interim Financial Statements (Un-Audited)
For the period 01 July 2024 to 31 March 2025

1.0 About the Company

1.01 Legal Form of the Company

Navana Pharmaceuticals PLC was incorporated in Bangladesh on 31 March 1986 vide registration no. C-15428/994 under the Companies Act-1913 (replaced by the Companies Act-1994) as a Private Company Limited by shares. The company was converted into a Public Limited Company on 30 December 2020.

1.02 Address of the Registered Office and Factory

The address of the Company's registered office and factory 1071,1073, North Rupshi, Tarabo, Municipality, Rupganj, Narayanganj. Corporate office address is House 99, Road 4, Block # B, Banani Dhaka-1213, Bangladesh. The Company has its factory in Rupshi, Narayanganj and several depots around the country.

1.03 Nature of Business Activities

The principal activities of the Company are manufacturing, distribution and marketing of pharmaceutical and veterinary products and sales of the produced items in the domestic and foreign market.

2.00 Basis of Preparation and Presentation of Financial Statements

2.01 Preparation and Presentation of Financial Statements of the Company

These Financial Statements are the unaudited Interim Financial Statements (here after 'the Interim Financial Statements') of Navana Pharmaceuticals PLC.

These interim financial statements should be read in conjunction with the Financial Statements for the year ended June 30, 2024 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information. The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting.

Interim Financial Reporting:

Interim period is a financial reporting period shorter than a full financial period. Interim financial report means a financial report containing either a complete set of financial statements (as described in IAS 1 Presentation of Financial Statements) or a set of condensed financial statements for an interim period.

IAS 34 requires that condensed Interim Financial Statements contain at a minimum:

- a condensed statement of financial position;
- a condensed statement or condensed statements of profit or loss and other comprehensive income;
- a condensed statement of changes in equity;
- a condensed statement of cash flows; and
- selected explanatory notes.

These Interim Financial Statements present selected explanatory notes that are intended to assist users in understanding the results of the operations of the company for the current interim period.

The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

2.02 Statement of Compliance

The Financial Statements have been prepared in compliance with the requirements of the Companies Act, 1994 and other relevant local laws as applicable and in accordance with the applicable International Accounting Standards (IASs), The Securities and Exchange Rules, 2020 and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and others laws and regulations applicable for the company.

2.03 Regulatory Compliances

As required by the company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- a) The Income Tax Ordinance 1984 and The Income Tax Act 2023;
- b) The Income Tax Rules 1984 and The Income Tax Act 2023;
- c) The Value Added Tax and Supplementary Duty Act 2012;
- d) The Value Added Tax and Supplementary Duty Rules 2016;
- e) The Customs Act, 1969;
- f) Bangladesh Labour Law, 2006 (Amended 2018);
- g) Negotiable Instrument Act, 1881; and
- h) The Securities and Exchange Rules, 2020.

2.04 Basis of Measurement

The Financial Statements have been prepared on a going concern basis under the historical cost convention applying accrual basis of accounting in accordance with the International Financial Reporting Standards (IFRS's).

The financial statements have been prepared on historical cost convention following the accrual concept of accounting, except for Property, plant & equipment which has been presented under the revaluation model. Investment in shares is valued at par value and cash flow statement has been prepared on cash basis.

2.05 Reporting Period and Comparative Information

The Financial Statements cover 09 months period starting from July 01, 2024 to March 31, 2025

Certain comparative amounts have been re-classified & rearranged to conform to the current period's presentation and all numerical information in the current financial statements as below:

- Statements of Financial Position as of the end of the preceding financial period;
- Statements of Comprehensive Income for the comparable of the preceding financial period;
- Statements of Changes in Equity for the comparable of the preceding financial period;
- Statement Cash Flows for the comparable of the preceding financial period;

Narrative and descriptive information for comparative information has also been disclosed as required by IAS & IFRS whenever it is relevant for the understanding of the current period financial statements.

2.06 Rearrangement of Financial Statement:

The previous period's figure has been rearrangement whenever considered necessary to ensure comparability with the current period presentation as per IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors".

2.07 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the company's functional currency. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

2.08 Property, Plant and Equipment (PPE)

Recognition and Measurement:

Items of property, plant & equipment are measured at cost or revalued amount less accumulated depreciation and impairment losses, if any in accordance with IAS 16: Property, Plant and Equipment. Cost includes expenditure that are directly attributable to the acquisition of the assets. The company has adopted 'Revaluation Model' for stating property, plant & equipment.

Maintenance Activities

The company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

Subsequent Costs

The cost of replacing a part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured reliably. All other repair and maintenances costs are charged to the Statement of Profit or Loss and Other Comprehensive Income during the financial period in which they incurred.

Retirements and Disposals

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets and net sales proceeds.

Depreciation

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provisions of IAS 16: Property, Plant and Equipment.

Depreciation on Property, Plant and Equipment has been compute during the periods using reducing balance method except Land & Land Development. Depreciation has been charged on addition when the related PPE are available.

After considering the useful life of assets as per IAS 16, the annual depreciation rates have been applied as under which is considered reasonable by the management.

Rate of Depreciation:

Particulars	Rate	Particulars	Rate
Land and Land Development		Vehicles	
Land and Land Development	Nil	Transport & Vehicles	20%
Building & Other Construction		Motor Cycle	20%
Factory Building	10%	Furniture & Fixture	
Office Decoration	10%	Furniture & Fixtures	10%
Pump House Construction	20%	Rack & Pallets	15%
Particulars	Rate	Particulars	Rate
Store Room	15%	Office Equipment's	
Office Room Extension	10%	Fire Extinguishers	15%
Factory Decoration	10%	Office Equipment's	15%
Factory Wall	10%	Air Cooler	20%
Pre Fabrication Building	10%	Cookeries & Cutleries	10%
Solvent Store	15%	Telephone Line Installation	15%
Plant & Machinery		Photocopier & Fax Machine	20%
Plant & Machinery	10%	Projector	15%
Electrical Installation	20%	Refrigerator	20%
Generator	20%	Mobile	20%
Gas Line Installation	20%	Computer & IT Accessories	
Spare Parts	20%	Computer	25%
ETP	20%	IT Accessories	30%
Electric Sub Station	20%	Other Assets	
Lab Equipment		Sundry Assets	15%
Quality Control Equipment	15%	Books	10%
Tools & Equipment's	15%	Software	20%

2.09 Intangible Assets

Software are amortized over 5 periods based on straight line method from the date when assets are available for use. The amount of amortization has been presented under the statement of rate of amortization on software is as under.

2.10 Events after the Reporting Period

Events after the reporting period that provide additional information about the company's position at the date of Statement of Financial Position or those that indicate that the going concern assumption is not appropriate are reflected in the financial statements. Events after reporting period that are not adjusting events are disclosed in the notes when material.

Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
3.00 Property, Plant and Equipment: Tk. 5,053,681,137			
	This is made up as follows: (details shown in Annex A)		
	Cost		
	Opening Balance	3,647,483,437	2,650,971,843
	Addition during the period	595,659,619	1,012,118,013
	Adjustment/disposal during the period	(312,784)	(15,606,419)
	Closing Balance	4,242,830,272	3,647,483,437
	Revaluation		
	Opening Balance	1,966,271,632	1,966,271,632
	Adjustment due to revaluation during the period	-	-
	Closing Balance	1,966,271,632	1,966,271,632
	Total Cost & Revaluation	6,209,101,903	5,613,755,069
	Depreciation		
	Opening Balance	962,813,731	806,861,796
	Charged during the period	192,802,790	171,251,750
	Adjustment during the period	(195,761)	(15,299,814)
	Closing Balance	1,155,420,760	962,813,731
	Written Down Value	5,053,681,137	4,650,941,337
3.01 Intangible Assets: Tk. 165,000			
	This is made up as follows:		
	Cost		
	Opening Balance	1,100,000	1,100,000
	Addition during the period	-	-
	Total Cost	1,100,000	1,100,000
	Depreciation		
	Opening Balance	770,000	550,000
	Charged during the period	165,000	220,000
	Closing Balance	935,000	770,000
	Written Down Value	165,000	330,000
4.00 Capital Work In Progress: Tk. 740,375,561			
	This is made up as follows:		
	Opening Balance	931,717,844	614,665,799
	Addition during the period:		
	Construction of New Utility and Engineering Building	90,745	31,773,650
	Refurbishment of Cephalosporin Unit	-	73,159,298
	BMRE and Machinery	302,354,621	939,095,421
	CWIP-New Generic Building 1	35,317,331	-
	Modernization and expansion of General liquid facility with dispensing area	-	37,977,309
	Modernization and expansion of Animal health facility	15,020,000	10,448,737
		1,284,500,541	1,707,120,214
	Less: Capitalized during the period		
	Capitalized in Factory Building	(544,124,980)	(775,402,370)
	Closing Balance	740,375,561	931,717,844
5.00 Right-of-Use Asset: Tk. 100,413,822			
	This is made up as follows: (Details shown in Annex B)		
	Written Down Value	100,413,822	163,404,672
6.00 Investment in Marketable Securities (Fair Value): Tk. 38,723,870			
	This is made-up as follows:		
	Opening total cost of marketable securities	200,063,544	214,420,832
	Cost value of sales of share	(17,328,616)	(14,357,288)
	Closing balance cost Value	182,734,928	200,063,544
	Unrealized gain/(loss)	(144,011,059)	(123,143,306)
	Closing market value securities	38,723,870	76,920,238

During the period total Realized Gain/(loss) from sale of marketable securities is (Tk.) (10,457,154)

Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
7.00 Inventories: Tk. 1,807,822,786			
	This is made-up as follows:		
	Raw Material	527,921,001	473,451,176
	Packing Material	140,769,532	141,963,452
	Finished Goods	926,518,111	565,590,306
	Work-in-Process	115,469,217	77,078,776
	Printed & Gifted Promotional Stock	97,144,926	25,105,000
	Total	1,807,822,786	1,283,188,710
8.00 Trade and Other Receivables: Tk. 832,694,779			
	This is made-up as follows:		
	Receivables-Local	699,304,875	915,824,397
	Receivables-Export	106,753,339	80,738,506
	Export Cash Incentive Receivable	26,345,189	23,106,132
	Interest Receivable on FDR	250,361	460,862
	Dividend Receivable	41,014	-
	Total	832,694,779	1,020,129,897
	Export Receivable as at 31 March 2025 total \$882,259 has been translated @ Tk. 121 average spot rate and resulting unrealized gain of Tk. 1,510,267 has been reported under 'FOREX Gain/Loss Account'.		
9.00 Advances, Deposits and Prepayments: Tk. 1,779,766,586			
	This is made-up as follows:		
	Advance for Suppliers (others)	34,697,188	86,570,654
	Advance for Raw/Packing Purchase	196,335,340	261,120,477
	LC Margin for Raw Material	61,435,871	117,828,568
	VAT Paid on Finished Goods	132,629,055	131,166,700
	Security Money	500,582	6,344,210
	Advance to Depot	54,486,886	44,189,884
	Advance Against Salary & Allowanc	9,610,529	11,977,354
	Advance Against Lease for Vehicles	847,524	847,524
	Advance Against Rent Sales Center	12,839,480	-
	Advance Against Customs Duty	19,939,823	23,662,933
	Advance Income Tax	635,773,672	520,416,189
	Advance for Capital Expense	604,701,636	920,949,505
	LC Margin for Capital Goods	15,969,000	26,020,000
	Total	1,779,766,586	2,151,093,999
10.00 Goods In Transit: Tk. 847,159,625		847,159,625	758,207,036
11.00 Cash and Cash Equivalents: Tk. 200,072,248			
	This is made-up as follows:		
	Cash at Bank		
	Jamuna Bank Ltd., Rupshi Br. A/c. 1661	3,345	211,619
	Pubali Bank Ltd., Dhaka Stadium Br. A/c 473	6,490,918	12,933,628
	Southeast Bank Ltd., Corporate Br. CD A/C No.648	916,439	1,106,015
	Southeast Bank Ltd., Corporate Br. CD A/C No 7614	290,954	328,852
	Dutch Bangla Bank Ltd., Local Office, CD A/C No.957	8,589,975	4,375,173
	Sonali Bank Ltd., Customs House Br. A/c 379	6,559,942	5,061,575
	Al Arafah Islami Bank Ltd., VIP Road Br. A./c-7189	236,056	6,466,843
	Al Arafah Islami Bank Ltd., VIP Road Br. ERQ A./c-46	222,045	1,580,147
	Al Arafah Islami Bank Ltd., VIP Road Br.DAD A./c-44	2,441,222	2,543,943
	United Commercial Bank Ltd., Gulshan Br., A./c-0011	13,123,235	21,411,461
	United Commercial Bank Ltd., Gulshan Br. A./c-0055	3,657	4,207
	United Commercial Bank Ltd., SND A.C-162	2,730	3,075
	Dhaka Bank Ltd.. Banani Br. A/c-28321	-	(237)
	NRBC Bank Ltd., Gulshan Br. -SND 033	99,200	99,200
	Shimanto Bank Ltd.Corp. Br., CD-012	944,009	2,895,595
	Community Bank BD Ltd.-9101	-	307,829
	Bengal Commercial Bank, Corp Br.-1467	1,001,783	292,139
	One Bank, Principal Br. A/c 9942	1,665	1,665
	Pubali Bank Ltd. Faridpur Br. A./c-160	23,801	1,115,563
	Pubali Bank Ltd., Mymensingh Br.- A/c 294	196,915	500,790
	Pubali Bank Ltd., Dargagate Br. A./c-125	1,156	285,130
	Pubali Bank Ltd., Kamalpur Br., A/c-25303	1,979	623
	Pubali Bank Ltd., Maizdee Court Br. A./c-840	230,180	823,985
	Pubali Bank Ltd., Momin Road Br. A./c-8940	8,520	2,624
	Southeast Bank Ltd., Barisal Br. A./c-051	2,630	3,915

Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
	Southeast Bank Ltd., Bogra Br. A./c-246	353	923
	Southeast Bank Ltd., Comilla Br. A./c-044	357	928
	Southeast Bank Ltd., Corporate Br.A./c-8200	2,811	3,270
	Southeast Bank Ltd., Cox's Bazar Br. A./c-091	435	54,900
	Southeast Bank Ltd., Dinajpur Br.-A/c 0144	724	2,020
	Southeast Bank Ltd., Jessore(SME) Br. A./c-347	476	936
	Southeast Bank Ltd., Joydevpur Br., A./c-027	7,259	10,891
	Southeast Bank Ltd., Khulna Br. A./c-925	385	845
	Southeast Bank Ltd., Rajshahi Br. A./c-014	1,159	1,954
	Southeast Bank Ltd., Rangpur Br. A./c-284	3,266	4,547
	United Commercial Bank, Br Ac-304	309,757	4,368
	United Commercial Bank, Br Ac-462	1,447	4,368
	United Commercial Bank, Br Ac-362	275,907	709,368
	United Commercial Bank, Br Ac-328	401,333	479,368
	United Commercial Bank, Br Ac-168	305,333	149,368
	United Commercial Bank, Br Ac-268	7,448	571,368
	United Commercial Bank, Br Ac-164	101,447	1,368
	United Commercial Bank, Br Ac-183	4,873	34,368
	United Commercial Bank, Br Ac-334	448	184,368
	United Commercial Bank, Br Ac-188	333	4,368
	United Commercial Bank, Br Ac-358	10,448	814,368
	United Commercial Bank, Br Ac-034	6,723	519,643
	United Commercial Bank, Br Ac-247	6,908	1,150,368
	United Commercial Bank, Feni-0138	871,528	604,988
	Standard Chartered Bank Ltd.Gulshan Br. Ac CD-28001	314,806	306,071
	United Commercial Bank, Tangail A/c-4138	6,674	299,938
	United Commercial Bank, Pabna A/c-8094	993	1,028
	United Commercial Bank, Feni A/c-138	871,527	-
	Prime Bank Banani Branch A/C 26074	5,685,234	-
	Dhaka Bank PLC.. Rupshi Br. A/c-000174	753,908	-
	City Bank Plc A/C # 6001	2,878	-
	Meghna Bank Plc # 110113500000181	841,098	4,195
	United Commercial Bank, Bond A/c-2258	3,620	4,166
	Commercial Bank of Ceylon PLC 7841	9,655	9,655
	AIBL SND , Ac # 0141220032027	138,042	10,381
	United Commercial Bank, N'Ganj Ac-10079	2,878	899,913
	FDR at IPDC AC-25213	3,000,000	3,000,000
	FDR at SCB AC-8001	30,000,000	30,000,000
	United Commercial Bank Ltd., IPO A/c-3209	67,831,632	120,119,623
	AIBL-141220031994 (13% Cash Dividend)	8,482,568	5,448,991
	United Commercial Bank Ltd. Ac-1971 (11% Cash Dividend)	4,669,949	2,338,190
	Meghna Bank Plc # 110113500000190 (14% Dividend)	5712801.83	-
	Cash in Hand	28,030,479	37,659,326
	Total	200,072,248	267,770,086

a. The reconciliation of bank balance has been performed and found in order.

b. Cash in hand has been counted by the management at the period end.

12.00 Paid-up Share Capital: Tk. 1,074,162,170

This is made-up as follows:

A. Authorised Capital:

200,000,000 Ordinary Shares of Tk. 10 each

2,000,000,000

2,000,000,000

B. Issued Subscribed & Paid up Capital:

107,416,217 Ordinary Shares of Tk. 10 each

1,074,162,170

1,074,162,170

Closing Balance

1,074,162,170

1,074,162,170

13.00 Share Premium: Tk. 44,170,069

Opening Balance

448,170,069

448,170,069

Addition during the period

-

-

Less: Adjustment for IPO Expenses

-

-

Closing Balance

448,170,069

448,170,069

The Company has issued 27,186,067 nos. of ordinary shares through IPO for aggregating Tk.750,000,000 , out of which 9,753,441 nos. of ordinary shares issued for Eligible Investors (EIs) and Employee & Others at the cut-off price Tk. 34 and remaining 17,432,626 nos. of ordinary shares at discounted price Tk.24 from the cut-off price i.e. Tk 34 per share for General Public (GP)including NRBs.

Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
14.00	Revaluation Reserve: Tk. 1,848,295,335		
	This is made-up as follows:		
	Opening Balance	1,848,295,335	1,848,295,335
	Less: Adjusted during the period	-	-
	Revaluation Reserve:	1,848,295,335	1,848,295,335
15.00	Loan from Directors: Tk. 30,000,000		
	This is made-up as follows:		
	Opening Balance	30,000,000	30,000,000
	Closing Balance	30,000,000	30,000,000
16.00	Lease Liabilities: Tk. 85,125,804		
	This is made-up as follows:		
	Opening balance	108,054,053	124,315,723
	Add: Addition during the year for ROUA for Vehicle & HO	16,360,533	-
	Less: Payment during the year	(39,288,783)	(16,261,670)
	Closing balance	85,125,804	108,054,053
16.01	Principal Payment due within one period	33,253,637	43,553,958
16.02	Principal Payment due within two to five period	51,872,167	64,500,095
	Total	85,125,804	108,054,053
17.00	Long Term Loan: Tk. 173,456,973		
	This is made-up as follows:		
17.01	Payment due within one period	111,547,220	35,366,036
17.02	Principal Payment due more than one year	61,909,753	115,319,266
	Total	173,456,973	150,685,302
18.00	Deferred Tax Liability: Tk. 173,972,956		
	This is made-up as follows:		
	Opening Balance	146,501,877	169,640,474
	Addition during the year:	5,908,483	-
	Total	152,410,360	146,501,877
	Less: Deferred Tax Asset	(21,562,596)	(11,503,594)
	Net Deferred Tax Liability Balance	173,972,956	158,005,471
19.00	Short Term Loan: Tk. 4,603,139,066		
	This is made-up as follows:		
	Bank Overdraft	1,862,241,624	1,886,549,502
	LTR, UPAS Loan	1,635,850,573	1,673,542,529
	Time Loan	987,274,420	1,334,659,639
	Margin Loan for Investment in Securities	117,772,449	113,439,831
	Total	4,603,139,066	5,008,191,502
20.00	Trade and Other Payables: Tk. 1,374,488,214		
	This is made-up as follows:		
	Trade & other Payables	47,869,806	23,791,543
	Salary Payables	105,885,811	110,666,864
	VAT Payable	56,124,094	53,676,568
	Payable Audit Fee	236,250	402,500
	Payable for Other Supplies	1,285,990	824,352
	Payable Director Remuneration	594,080	584,290
	Payable-Sales Center Rent	1,823,258	1,421,075
	Payable for Utility	3,596,212	701,891
	Provision for Gratuity	54,100,383	70,184,257
	Provision for Bad Debt	16,553,209	13,064,358
	Provision for Broken, Damage & Expiry	24,958,012	312,486
	Provision for Income Tax	564,085,462	451,200,564
	Provision for W.P.P.F	17,200,189	25,139,919
	Interest Payable on Short Term Loan	198,054,106	167,225,310
	Interest Payable on Term Loan	1,094,908	949,389
	Interest Payable on Lease Liability	747,340	-
	Withholding Tax Payable	5,267,357	4,049,848
	Payable for Earned Leave Encashment	13,367,853	13,367,853
	Payable for TDS and VDS for Capex	258,843,894	262,343,894
	Payable for interest on Bond	2,800,000	-
	Total	1,374,488,214	1,199,906,960

Notes	Particulars	Amount in BDT	
		01 Jul'24-31 Mar'25	01 Jul'23-31 Mar'24
21.00	Sales: Tk. 6,604,436,742		
	This is made-up as follows:		
	Local Sales Human Health	6,226,252,999	4,697,934,229
	Export Sales	302,722,998	168,832,129
	Local Sales Animal Health	1,171,958,936	1,011,867,568
	Gross sales	7,700,934,933	5,878,633,926
	Less: Value Added Tax (VAT)	1,096,498,191	846,256,825
	Net sales	6,604,436,742	5,032,377,101
	Breakup of Net Turnover		
	Local Sales Human Health Division	5,303,452,299	4,001,647,555
	Export Sales	302,722,998	168,832,129
	Local Sales Animal Health Division	998,261,445	861,897,417
	Total	6,604,436,742	5,032,377,101
	a. Sales figure is presented on net of VAT in the statement of profit or loss and other comprehensive income.		
	b. Sales has increased due to strong branding, marketing and improved economic condition.		
22.00	Cost of Sales: Tk. 3,565,890,580		
	This is made-up as follows:		
	Raw Material Consumption (Note No: 21.01)	2,387,947,364	1,849,430,700
	Packing Material Consumption (Note No: 21.02)	1,187,456,416	764,909,571
	Factory Expenses (Note No: 21.03)	461,499,366	376,722,004
	Total Manufacturing Cost	4,036,903,145	2,991,062,275
	Opening Stock Work-In-Process	77,078,776	96,348,470
	Closing Stock Work-In-Process	(115,469,217)	(104,947,905)
	Cost of Production	3,998,512,704	2,982,462,841
	Opening Stock Finished Goods	565,590,306	508,936,313
	Finished goods available for sale	4,564,103,011	3,491,399,154
	Cost of Physician Sample transferred to Marketing Exp.	(33,361,740)	(26,658,648)
	Cost of Bonus Product transferred to Marketing Exp.	(38,332,580)	(24,255,215)
	Closing Stock Finished Goods	(926,518,111)	(701,977,332)
	Cost of Goods Sold	3,565,890,580	2,738,507,959
22.01	Raw Material Consumption: Tk. 2,387,947,364		
	This is made-up as follows:		
	Opening Stock of Raw Materials	473,451,176	378,760,941
	Add: Purchase during the period	2,442,417,188	1,769,867,528
	Less: Closing Stock of Raw Materials	(527,921,001)	(299,197,769)
	Total	2,387,947,364	1,849,430,700
22.02	Packing Material Consumption: Tk. 1,187,456,416		
	This is made-up as follows:		
	Opening Stock of Packing Materials	141,963,452	113,570,761
	Add: Purchase during the period	1,186,262,496	790,841,664
	Less: Closing Stock of Packing Materials	(140,769,532)	(139,502,854)
	Total	1,187,456,416	764,909,571
22.03	Factory Expenses: Tk. 461,499,366		
	This is made-up as follows:		
	Salary & Allowance	129,640,930	134,001,682
	Festival Bonus	14,442,941	14,336,291
	Contribution to Provident Fund	7,254,619	4,995,077
	Holiday Allowance & Overtime	15,769,112	12,826,326
	Cylinder Expenses	-	522,000
	Diesel for generator	8,129,430	4,782,553
	Electricity Bill	25,958,705	28,342,970
	Entertainment	644,784	3,210,422
	Renewal Fees	260,498	413,235
	Fees & Forms	15,733	465,056
	Insurance Premium-Fire & Burglary	3,240,379	1,178,511
	Gas Bill	1,652,243	1,546,424
	Earned leave encashment	4,361,395	-
	Group Insurance Premium	-	59,510
	Laboratory Chemicals	22,385,044	12,255,541
	Medical Expenses	33,850	32,958

Notes	Particulars	Amount in BDT	
		01 Jul'24-31 Mar'25	01 Jul'23-31 Mar'24
	Newspaper & Periodicals	12,438	2,469
	Repair & Maintenance	18,431,588	5,309,084
	Medical Waste Management Expense	2,258,481	1,408,959
	Sanitation Expense	5,493,000	2,435,268
	Spare Parts for machinery	10,690,785	12,168,318
	Depreciation on PPE & ROUA	141,072,416	104,362,549
	Other Business Expenses	49,750,996	32,066,800
	Total	461,499,366	376,722,004

23.00 Administrative Expenses: Tk. 157,651,134

This is made-up as follows:

Salary and Allowances	59,377,125	54,653,381
Festival Bonus	8,559,959	5,969,279
Contribution to Provident Fund	3,454,795	3,943,473
Gratuity	4,648,302	3,750,000
Earned leave encashment	3,878,146	-
Audit Fees	316,875	262,500
Board Meeting Fee	517,000	555,500
Audit Committee & NRC Meeting Fee	467,500	236,500
Professional Fees	2,900,663	973,998
Advertising Expenses	1,460,502	1,257,352
Director's Remuneration	5,970,000	7,542,000
Electricity Bill	2,118,153	2,396,593
Registration Fees and Renewal Fees	497,015	742,348
Foreign Tour Expenses	3,180,808	7,330,176
Depreciation on Rental Asset (Annex-ROUA)	7,824,607	5,628,055
Depreciation Other than Rental Asset (Annex-PPE)	18,539,816	14,107,083
Amortization on Software	165,000	165,000
Other Business Expenses	33,774,868	33,821,349
Total	157,651,134	143,334,588

As per IFRS 16-Leases Office Rent for current period has been presented under Depreciation.

24.00 Selling & Marketing Expenses: Tk. 1,369,257,119

This is made-up as follows:

Salary and Allowances	685,772,871	482,628,265
Festival Bonus	71,348,875	67,102,973
Contribution to Provident Fund	34,528,802	27,487,980
Incentives	45,692,827	18,095,784
Gratuity	5,174,266	2,250,000
Stationery	1,318,340	2,463,213
Daily Expenses for Field workers	269,422,997	264,801,180
Earned leave encashment	8,206,528	-
Travelling and Conveyance	8,196,919	5,811,414
Bonus On Sales	38,332,580	24,255,215
Printed & Gifted Promotional Expenses	52,959,072	28,068,144
Sample Expenses	33,361,740	26,658,648
Depreciation on PPE & ROUA	15,058,269	9,384,810
Product Expiry Replacement	31,280,081	23,074,997
Brand Development & New Product	10,404	4,515,763
Other Business Expenses	68,592,548	76,687,663
Total	1,369,257,119	1,063,286,050

25.00 Distribution Expenses: Tk. 414,519,918

This is made-up as follows:

Salary and Allowances	123,524,109	115,037,500
Festival Bonus	17,001,359	13,850,835
Contribution to Provident Fund	7,125,995	4,177,151
Repair & Maintenance	4,532,819	2,139,607
Stationery	5,594,068	4,696,003
Earned Leave Encashment	3,931,486	-
Daily Expenses for Field workers	56,128,715	50,512,016
Holiday Allowance & Overtime	6,983,639	3,723,291
Insurance Premium Fire & Burglary	498,000	254,179
Group Insurance Premium	-	99,510
Depreciation on PPE & ROUA	89,772,275	56,764,583
Other Business Expenses	99,427,454	98,564,452
Total	414,519,918	349,819,128

Notes	Particulars	Amount in BDT	
		01 Jul'24-31 Mar'25	01 Jul'23-31 Mar'24

26.00 Finance Expenses: Tk. 565,981,270

This is made-up as follows:

Interest Charged on Short term loan	522,101,106	253,464,057
Interest on Term Loan	8,428,010	10,177,592
Bank Charges	5,548,144	5,412,416
Interest on Other Loan/(Bond)	8,490,795	-
Bank Charges-Export	992,945	3,454,032
BO Charges, Interest on Margin Loan	10,016,975	12,522,546
Interest on Lease Finance	10,403,296	12,637,883
Total	565,981,270	297,668,525

27.00 Other Income/ (Loss): Tk. -25,119,893

This is made-up as follows:

Cash Incentive	16,376,577	10,260,111
Bank Interest	305,240	119,280
Interest on FDR	436,391	189,645
Dividend Income	901,146	930,336
Sale of Wastage	4,068,337	4,153,176
FOREX Gain/(Loss)	(38,466,927)	(24,200,924)
Gain on disposal of FA	(74,523)	1,460,000
Realized Gain/(loss) from Sale of Marketable Securities	(10,457,145)	971,866
Income from PF Contribution Forfeiture	1,791,012	7,620,588
Total	(25,119,893)	1,504,079

28.00 Income Tax: Tk. 106,976,415

This is made-up as follows:

Current Period Tax	112,884,898	88,717,806
Deferred Tax Expense/ (Income)	(5,908,483)	(71,700)
Total	106,976,415	88,646,106

29.00 Earnings Per Share (EPS)

Earnings Attributable to the Ordinary Shareholders	374,944,373	331,606,209
Weighted Avg. Number of Ordinary Shares	107,416,217	107,416,217
Earnings Per Share (EPS)	3.49	3.09

Reasons for Deviation: Increment of Earnings per Share in the reporting period by 12.94% because of growth of Sales Revenue as well as optimum cost management policy.

Weighted Average Number of Ordinary Shares Outstanding: The weighted average number of ordinary shares outstanding during the year is the number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares issued during the year multiplied by a time-weighted factor. The time-weighted factor is the number of days that the shares are outstanding as a proportion of the total number of days in the year (considering 365 days in a period).

Weighted Average Number of Ordinary Shares Outstanding during the year:

Date of Allotment	Ordinary Shares Nos	Weighted no. days	Calculation	Weighted no. Shares
OS Shares as on 1st July ,2022	80,230,150	100%		80,230,150
16/10/2022	23,201,750	365	(23,201,750*365/365)	23,201,750
19/10/2022	3,984,317	365	(3,984,317*365/365)	3,984,317
Closing Balance as on 31-03-2025	107,416,217			107,416,217

29.01 Dilution of Earnings Per Share: No diluted earnings per share is required to be calculated for the period presented as there was no item issued by the company, as such no scope for dilution of shares during the period.

Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
30.00	Net Asset Value (NAV) Per Share	31-Mar-2025	30-June-2024
	Total Assets	11,400,875,414	11,303,703,819
	Less Total Liabilities	6,533,154,247	6,742,608,259
	Net Assets	4,867,721,167	4,561,095,560
	Number of Ordinary Shares	107,416,217	107,416,217
	Net Asset Value (NAV) Per Share	45.32	42.46
31.00	Net Operating Cash Flow Per Share (NOCFPS)		
	Net Cash Generated from Operating Activities	1,098,150,059	171,000,086
	Number of Ordinary Shares	107,416,217	107,416,217
	Net Operating Cash Flow Per Share (NOCFPS)	10.22	1.59

Reasons for Deviation: Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 10.22 from Tk. 1.59 due to cash received from the customers was higher than the cash payment for operation in the reporting period.

32.00 Reconciliation of Cash Flows from Operating Activities

A reconciliation of net income or net profit with cash flow from operating activities:

	July2024-March'2025	July2023-March'2024
Net Profit before tax	481,920,788	420,252,315
Adjustment to reconcile net income to net cash provided by operating activities:		
Depreciation and Amortization	272,319,175	190,247,081
Realized Gain/(loss) on Marketable Securities	(10,457,145)	(971,866)
Dividend Income	(901,146)	(930,336)
Unrealized Foreign Exchange Gain/(Loss)	(38,466,927)	26,182
Bank & Lease Interest	534,259,615	297,668,525
WPPF Provision	17,200,189	21,012,616
Income Tax Paid	115,357,483	(52,173,590)
Increase/Decrease in Current Assets:		
Inventory and Goods in transit (Increase)	(613,586,665)	(128,554,587)
Accounts Receivable (Increase)	187,435,119	(82,160,674)
Advance Deposit & Prepayment (Increase)	319,453,947	114,439,847
Increase/Decrease in current Liabilities:		
Trade and Other Payables (Decrease)	(166,384,375)	(163,162,925)
Net Cash Generated by Operating Activities	1,098,150,058	615,692,588

33.00 Events After the Reporting Period

There are no significant events after the reporting period to present.

34.00 Related Party Disclosure

The name of the related parties nature of transaction and their respective period end balance have been set out in accordance with the provisions of Para 18 Disclosure of Transaction between Related Parties of IAS 24 'Related Party Disclosure's. The company in normal course of business carried out transactions at fair value with following related parties:

Name of the Related Party	Relationship	Nature of Transaction	Balance as at 1 July 2024	Transaction July'24-Mar'25	Balance as at 31 Mar 2024
Professor Dr. Jonaid Shafiq	Managing Director	Remuneration	308,320	2,671,782	303,863
Dr. Sayeed Ahmed	Deputy Managing Director	Remuneration	275,970	2,340,540	282,467

As per Para-17, IAS 24: An entity shall disclose key management personnel compensation in total and for each of the following

(a) Short-term Employee Benefits	Designation	Particulars	Transaction during the period	Outstanding as on 31-03-2024
Name				
Professor Dr. Jonaid Shafiq	Managing Director	Director Remuneration	2,671,782	303,863
Dr. Sayeed Ahmed	Deputy Managing Director	Director Remuneration	2,340,540	282,467

Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024

35.00 Contingent Assets

There was no contingent assets as at 31 March 2025.

36.00 Contingent Liability

110,976,846

110,976,846

37.00 Litigation Pending

1. For Non-payment of VAT which the legal experts estimated cost is Tk. 40,000,000/-. It has been stayed by High Court till 04-11-2024
2. VAT demand of Tk. 31,982,604.12/- for Animal Health Product- "Pusti Premix". It was stayed by High Court on 14-01-2016 until final verdict of court.
3. Demand for Non-payment of VAT & interest to the extent of Tk. 8,666,739.22 by Customs Excise & VAT Commissionerate Dhaka (East) against Navana Health Care past audit reports. It has been stayed by High Court till 28-08-2024.
4. A petition is filed with High Court against unreasonable demand of Tk. 30,327,503 by Income Tax Tribunal u/s 83(2)/156/159 for AY 2015-16 (11 month).
5. A petition has been filed with Jugma Zilla Judge Court of Narayangonj for reclaiming 30 decimal land opposite of Factory at Rupshi Rupgonj. It is expected to be favorable.

37.01 Bank Guarantee on behalf of the company provided by following Banks:

1. Al-Arafah Islami Bank PLC, VIP Road Branch-Tk. 8,245,391.52/-.
2. Bengal Commercial Bank PLC, Head Office-Tk. 6,56,500/-.
3. Community Bank Bangladesh PLC, Corporate Branch-Tk. 81,53,881.49/-.

38.00 Events after the Reporting Period

Navana Pharmaceuticals PLC. allotted total 23,201,750 no's shares to General & EI Shareholders and 3,984,317 nos shares to Employees & Other Shareholders on 16-10-2022 and 19-10-2022 respectively to raise the IPO Proceed of Tk.75.00 crore

39.00 Unclaim Dividend Payable: Tk. 12,971,233

Year wise Break-up

2021-2022

2022-2023

2023-2024

Total

31-Mar-2025

30-June-2024

12,971,233

7,764,971

2,024,967

2,336,928

5,235,359

5,428,043

5,710,907

-

12,971,233

7,764,971


Finance Director & CFO


Company Secretary


Acting Managing Director


Director


Director

Navana Pharmaceuticals PLC.
Schedule of Property, Plant and Equipment
As at 31 March 2025

SL No.	Particulars	COST										Dep. Rate	DEPRECIATION				Written Down Value 31 Mar 2025	Written Down Value 30 June 2024
		Balance as on 01 July 2024			Addition			Adjustment	Balance as on 31 Mar 2025				Balance as on 01 July 2024	Charged during the year	Adjustment	Balance as on 31 Mar 2025		
		Cost	Revaluation Reserve	Total	Cost	Revaluation Reserve	Total		Cost	Revaluation Reserve	Total							
1	Land and Land Development	516,631,355	1,966,271,633	2,482,902,988	-	-	-	-	516,631,355	1,966,271,633	2,482,902,988	0%	-	-	-	-	2,482,902,988	2,482,902,988
2	Building & Other Construction	1,414,819,374	-	1,414,819,374	284,718,200	-	284,718,200	-	1,699,537,574	-	1,699,537,574	10%	345,532,818	86,033,122	-	431,565,942	1,267,971,632	1,069,286,556
	Factory Building	1,332,778,148	-	1,332,778,148	284,718,200	-	284,718,200	-	1,617,496,348	-	1,617,496,348	10%	307,805,087	82,709,249	-	390,514,336	1,226,982,012	1,024,973,062
	Office Decoration	17,328,480	-	17,328,480	-	-	-	-	17,328,480	-	17,328,480	10%	10,060,567	-	-	10,605,660	6,722,820	7,267,913
	Pump House Construction	3,970	-	3,970	-	-	-	-	3,970	-	3,970	20%	-	-	-	3,970	-	-
	Store Room	27,480	-	27,480	-	-	-	-	27,480	-	27,480	15%	-	27	-	27,271	209	236
	Office Room Extension	829,201	-	829,201	-	-	-	-	829,201	-	829,201	10%	727,953	7,594	-	735,547	93,654	101,248
	Factory Decoration (BMRD)	48,150,595	-	48,150,595	-	-	-	-	48,150,595	-	48,150,595	10%	14,432,189	2,528,880	-	16,961,069	31,189,526	33,718,406
	Factory Wall	3,177,143	-	3,177,143	-	-	-	-	3,177,143	-	3,177,143	10%	2,440,192	55,271	-	2,495,463	681,680	736,952
	Pre Fabrication Building	12,445,429	-	12,445,429	-	-	-	-	12,445,429	-	12,445,429	10%	9,966,067	185,952	-	10,152,019	2,293,410	2,479,362
	Solvent Store	78,928	-	78,928	-	-	-	-	78,928	-	78,928	15%	69,551	1,055	-	70,606	8,322	9,377
3	Plant & Machinery	1,322,674,143	-	1,322,674,143	285,153,296	-	285,153,296	-	1,607,827,439	-	1,607,827,439	15%	432,588,991	84,938,193	-	517,527,185	1,090,300,255	890,085,153
	Plant & Machinery	1,275,934,972	-	1,275,934,972	285,153,296	-	285,153,296	-	1,561,088,268	-	1,561,088,268	10%	393,360,731	83,750,923	-	477,111,654	1,083,976,614	882,574,242
	Electrical Installation	23,147,818	-	23,147,818	-	-	-	-	23,147,818	-	23,147,818	20%	18,958,472	628,871	-	19,587,343	3,560,475	4,189,346
	Generator	14,447,896	-	14,447,896	-	-	-	-	14,447,896	-	14,447,896	20%	12,324,351	378,696	-	12,703,047	1,744,849	2,123,545
	Gas Line Installation	3,101,333	-	3,101,333	-	-	-	-	3,101,333	-	3,101,333	20%	2,206,929	134,161	-	2,341,090	760,243	894,404
	Spare Parts	1,501,405	-	1,501,405	-	-	-	-	1,501,405	-	1,501,405	20%	1,380,170	18,185	-	1,398,355	103,050	121,235
	ETP	660,080	-	660,080	-	-	-	-	660,080	-	660,080	20%	530,822	19,389	-	550,211	109,869	129,258
	Electric Sub Station	3,880,639	-	3,880,639	-	-	-	-	3,880,639	-	3,880,639	20%	3,827,517	7,968	-	3,835,485	45,154	53,122
4	Lab Equipment	118,336,060	-	118,336,060	2,247,474	-	2,247,474	-	120,583,534	-	120,583,534	15%	72,559,806	5,218,270	-	77,778,076	42,805,458	45,776,254
	Quality Control Equipment	114,974,900	-	114,974,900	2,247,474	-	2,247,474	-	117,222,374	-	117,222,374	15%	69,529,833	5,170,969	-	74,700,802	42,521,572	45,445,067
	Tools & Equipment's	3,361,160	-	3,361,160	-	-	-	-	3,361,160	-	3,361,160	15%	3,029,973	47,301	-	3,077,274	283,886	331,187
5	Furniture & Fixture	62,126,502	-	62,126,502	9,427,937	-	9,427,937	-	71,554,439	-	71,554,439	15%	26,669,226	3,748,227	-	30,417,453	41,136,986	35,457,276
	Furniture & Fixtures	33,456,435	-	33,456,435	2,238,837	-	2,238,837	-	35,695,272	-	35,695,272	10%	18,405,408	1,225,218	-	19,630,626	16,064,647	15,051,027
	Rack & Pallets	28,670,067	-	28,670,067	7,189,100	-	7,189,100	-	35,859,167	-	35,859,167	15%	8,263,818	2,523,009	-	10,786,827	25,072,340	20,406,249
6	Office Equipment's	47,908,014	-	47,908,014	7,566,095	-	7,566,095	312,784	55,161,325	-	55,161,325	15%	33,133,088	2,408,719	195,761	35,346,046	19,815,279	14,774,927
	Fire Extinguishers	1,074,615	-	1,074,615	-	-	-	-	1,074,615	-	1,074,615	15%	945,520	14,523	-	960,043	114,572	129,095
	Office Equipment's	19,319,609	-	19,319,609	368,750	-	368,750	-	19,688,359	-	19,688,359	15%	13,847,426	635,414	-	14,482,840	5,205,519	5,472,183
	Air Cooler	21,052,934	-	21,052,934	7,194,345	-	7,194,345	312,784	27,934,495	-	27,934,495	20%	12,596,637	1,670,835	195,761	14,071,711	13,862,784	8,456,297
	Cookeries & Cutleries	416,096	-	416,096	-	-	-	-	416,096	-	416,096	10%	338,275	5,837	-	344,112	71,984	77,821
	Telephone Line Installation	1,192,479	-	1,192,479	3,000	-	3,000	-	1,195,479	-	1,195,479	15%	1,003,020	21,314	-	1,024,334	171,145	189,459
	Photocopier & Fax Machine	441,300	-	441,300	-	-	-	-	441,300	-	441,300	20%	405,399	5,385	-	410,784	30,516	35,901
	Projector	770,500	-	770,500	-	-	-	-	770,500	-	770,500	15%	591,459	20,142	-	611,601	158,899	179,041
	Refrigerator A/H	1,703,275	-	1,703,275	-	-	-	-	1,703,275	-	1,703,275	20%	1,500,296	30,447	-	1,530,743	172,532	202,979
	Mobile	1,937,206	-	1,937,206	-	-	-	-	1,937,206	-	1,937,206	20%	1,905,056	4,823	-	1,909,879	27,328	32,150
7	Transport	106,726,523	-	106,726,523	-	-	-	-	106,726,523	-	106,726,523	10%	8,001,495	7,404,627	-	15,406,122	91,320,401	98,725,028
	Vehicle	106,726,523	-	106,726,523	-	-	-	-	106,726,523	-	106,726,523	10%	8,001,495	7,404,627	-	15,406,122	91,320,401	98,725,028
8	Computer & IT Accessories	50,322,470	-	50,322,470	5,923,870	-	5,923,870	-	56,246,340	-	56,246,340	25%	38,153,888	2,819,134	-	40,973,022	15,273,318	12,168,582
	Computer	40,568,759	-	40,568,759	5,923,870	-	5,923,870	-	46,492,629	-	46,492,629	25%	28,879,389	2,729,115	-	31,608,504	14,884,125	11,689,370
	Hardware & Networking Installator	9,753,711	-	9,753,711	-	-	-	-	9,753,711	-	9,753,711	25%	9,274,499	90,019	-	9,364,518	389,193	479,212
9	Other Assets	7,938,991	-	7,938,991	622,745	-	622,745	-	8,561,736	-	8,561,736	15%	6,174,419	232,498	-	6,406,917	2,154,819	1,764,572
	Sundry Assets	7,012,304	-	7,012,304	485,745	-	485,745	-	7,498,049	-	7,498,049	15%	5,309,568	227,860	-	5,537,428	1,960,621	1,702,736
	Books	926,687	-	926,687	137,000	-	137,000	-	1,063,687	-	1,063,687	10%	864,851	4,638	-	869,489	194,198	61,836
	TOTAL 31 March 2025:	3,647,483,433	1,966,271,634	5,613,755,067	595,659,618	-	595,659,618	312,784	4,242,830,267	-	4,242,830,267	-	962,813,730	192,802,790	195,761	1,155,420,763	5,053,681,137	4,650,941,337
10	Intangible Assets	-	-	-	-	-	-	-	-	-	-	20%	770,000	165,000	-	935,000	165,000	550,000
	Software	1,100,000	-	1,100,000	-	-	-	-	1,100,000	-	1,100,000	20%	770,000	165,000	-	935,000	165,000	550,000

Allocation of depreciation:					
Particulars	Total	Admin	Factory	Sales & Mkt	Dist.
PPE excl Vehicle	185,398,163	18,539,816	129,778,714	7,415,927	29,663,706
Vehicle	7,404,627	-	-	-	7,404,627

Navana Pharmaceuticals PLC.

Schedule of Right-of-Use Asset

As at 31 March 2025

SL No.	Particulars	Cost				Dep. Rate	Depreciation				Written Down Value as on 31 Mar 2025	Written Down Value as on 30 June 2024
		Balance as on 1 July 2024	Addition	Adjustment	Balance as on 31 Mar 2024		Balance as on 1 July 2024	Charged during the year	Adjustment	Balance as on 31 Mar 2025		
		Cost	Cost		Total							
1	Rental Asset	16,952,283	16,360,533	-	33,312,816		7,064,023	4,060,040	-	11,124,063	22,188,754	9,888,260
	Rental Asset	16,952,283	16,360,533	-	33,312,816		7,064,023	4,060,040	-	11,124,063	22,188,754	9,888,260
2	Vehicles	501,942,299	-	-	501,942,299		348,425,886	75,291,345	-	423,717,231	78,225,068	153,516,413
	Transport & Vehicles	321,673,275		-	321,673,275	20%	222,456,345	48,250,991	-	270,707,336	50,965,939	99,216,930
	Motor Cycle	180,269,024	-	-	180,269,024	20%	125,969,541	27,040,354	-	153,009,895	27,259,129	54,299,483
	Total	518,894,582	16,360,533	-	535,255,115		355,489,909	79,351,385	-	434,841,294	100,413,822	163,404,673

Allocation of depreciation:

	Total	Admin	Factory	Sales & Mkt	Dist.
On Vehicles	75,291,345	3,764,567	11,293,702	7,529,134	52,703,941
On Rent HO	4,060,040	4,060,040	-	-	-

Navana Pharmaceuticals PLC.
House 99, Road 04, Block B, Banani, Dhaka 1213
TIN: 187576149869/Taxes Circle 156 (Companies)

COMPUTATION OF TOTAL INCOME AND TAX LIABILITY
Assessment Year 2025-26
Income Year ended 31 March 2025

		Amounts in Taka
NET PROFIT, BEFORE TAXATION		
- As per Profit and Loss Statement		48,19,20,788
Less: Other income -		
Cash incentive	1,63,76,577	
Bank interest	3,05,240	
Interest on FDR	4,36,391	
Dividend income	901,146	
Sale of wastage	40,68,337	
Gain on disposal of FA	-74,523	
Realized Gain/(loss) on Share Sell	-10,457,145	
PF Forfeiture	17,91,012	
		1,33,47,034
		46,85,73,755
ADDITIONS FOR SUBSEQUENT/ SEPERATE CONSIDERATIONS		
Add: Accounting depreciation	26,82,59,135	
- Depreciation on ROUA	4,060,040	
- Entertainment	73,95,945	
- Incentive	4,56,92,827	
- Sample expenses	3,33,61,740	
- Gratuity provision	1,50,00,000	
- WPPF provision	4,30,12,722	
- Broken/ damaged provision	2,27,06,897	
- Promotional Expense	5,29,59,072	
- Bad debt provision	63,01,714	
- Interest On Loan	56,59,81,270	
- Foreign tour	1,01,72,547	
		107,49,03,910
		154,34,77,664
ADJUSTMENTS FOR STATUTORY DISALLOWANCES		
Less : Depreciation as per Income Tax Act 2023		348,072,064
Less : Rent of ROUA		4,060,040
Less: Interest Paid On Loan		53,42,59,615
		65,70,85,945
Less: Sample expenses		
Total turnover	6,604,436,742	
On first 5 crore @ 2%	1,000,000	
On Next 5 crore @ 1%	500,000	
Balance @ 0.5%	32,522,184	
Allowable	34,022,184	3,40,22,184
		62,30,63,761
Add: Profit on disposal of vehicle		62,30,63,761
Less: Gratuity paid	1,04,50,000	
WPPF Paid	2,58,12,533	
Bad debt written off	3,12,159	
Incentive @10% of Profit	4,81,92,079	
Foreign tour @ 0.5% of disclosed turnover or the actual expenditure, whichever is less.	1,01,72,547	
		12,79,61,502
		49,51,02,259
Less: Entertainment allowance permissible as per rule , on profit before tax claim of entertainment allowance @4% on the first Taka 10,00,000 of income at @ 2% on the balance income.The lower amount is allowed, as permissible.		73,95,945
		48,77,06,314
Less:		
Export sale @ 7%		2,23,54,657
INCOME FROM LOCAL BUSINESS		46,53,51,657
INCOME FROM EXPORT BUSINESS		2,23,54,657
Total		48,77,06,314

Navana Pharmaceuticals PLC.
House 99, Road 04, Block B, Banani, Dhaka 1213
TIN: 187576149869/Taxes Circle 156 (Companies)

COMPUTATION OF TOTAL INCOME AND TAX LIABILITY
Assessment Year 2025-26
Income Year ended 31 March 2025

<u>Add: Other income -</u>			
Cash incentive	1,63,76,577		
Bank interest	3,05,240		
Interest on FDR	4,36,391		
Sale of wastage	40,68,337		
Gain on disposal of FA	-74,523		
Dividend Income	9,01,146		
Realized Gain from Share Sale	(10,457,145)		
INCOME FROM OTHER INCOME			1,33,47,034
TOTAL INCOME			50,10,53,348
<u>Calculation of minimum tax</u>			
(i) (a) On business income @ 22.5%	10,47,04,123		
(b) On other income excluding Capital Gain @ 20%	12,44,243	10,59,48,366	
(ii) On turnover @ 0.60%		3,96,26,620	
Minimum tax -- higher of (i) and (ii)			10,59,48,366
<u>Calculation of tax on export income</u>			
(i) Tax at regular rate @20%		26,82,559	
Less: Rebate @ 50% (under paragraph 28 of Part A of the Sixth Schedule)		13,41,279	
		13,41,279	
(ii) Tax deducted at source		30,02,894	
Minimum tax -- higher of (i) and (ii)			30,02,894
<u>Calculation tax on Cash Incentive:</u>			
Cash Incentive tax thereon 22.5%		3,684,730	36,84,730
<u>Calculation tax on Bank Interest:</u>			
Bank Interest tax thereon 22.5%		68,679	68,679
<u>Calculation tax on Dividend:</u>			
Dividend tax thereon 20%		180,229	1,80,229
Total Tax Liability			11,28,84,898

Navana Pharmaceuticals PLC

TIN: 187576149869/Taxes Circle 156 (Companies)

Calculation of deferred tax

Assessment Year 2025-26

Income for the year ended 31 March 2025

Deferred tax liability/(asset)

Particulars	Carrying amount of assets and liabilities as at 31-03-25	Tax base value of assets and liabilities as a 31-03-2025	Taxable/(Deductible) temporary difference	DTL	DTA	Opening Balance	Current Yr Charge
	Taka	Taka	Taka	Taka	Taka	Taka	Taka
PPE	2,570,778,149	2,185,483,922	385,294,226	86,691,201	-	28,525,579	58,165,622
Revaluation Reserve	-	-	-	-	-	117,976,298	-
ROUA	100,413,822	204,048,547	(103,634,725)	(23,317,813)	-	-	(23,317,813)
Intangible	165,000	633,600	(468,600)	(105,435)	-	-	(105,435)
Lease liability Vehicle	(82,412,184)	-	(82,412,184)	-	(18,542,741)	-	(18,542,741)
Lease liability ROUA	(2,713,619)	-	(2,713,619)	-	(610,564)	-	(610,564)
Marketable Securities	38,723,870	182,734,928	(144,011,058)	-	(14,401,106)	-	(14,401,106)
Prov. For Gratuity	(15,000,000)	10,450,000	(4,550,000)	-	(1,023,750)	-	(1,023,750)
Interest Paid On Loan	565,981,270	534,259,615	31,721,655	-	7,137,372	-	7,137,372
Prov. For WPPF	(17,200,189)	-	(17,200,189)	-	(3,870,043)	-	(3,870,043)
Prov. For Broken, Damage, Expiry	(24,958,012)	-	(24,958,012)	-	(5,615,553)	-	(5,615,553)
Prov. For Bad debt	(16,553,209)	-	(16,553,209)	-	(3,724,472)	-	(3,724,472)
Net temporary difference	3,117,224,897	3,117,610,613	20,514,284	63,267,953	(40,650,857)	146,501,877	(5,908,483)